The phenotypic spectrum of patients carrying NR5A1 mutations ranges from 46,XY gonadal dysgenesis to male infertility. Phenotypic variability could be due to digenic or oligogenic inheritance of pathogenic variants in other testis-determining genes. Here, exome sequencing identified 2 pathogenic de novo NR5A1 mutations in 2 patients with 46,XY gonadal dysgenesis, p.Q206Tfs*20 and p.Arg313Cys. The latter patient also carried a missense mutation in MAP3K1. Our data extend the number of NR5A1 gene mutations associated with gonadal dysgenesis. The combination of an NR5A1 mutation with a MAP3K1 variant may explain the phenotypic variability associated with NR5A1 mutations.

Keywords:
46,XY complete gonadal dysgenesis, Disorders of sex development, MAP3K1, NR5A1, Sex determination
1.
Allali S, Muller JB, Brauner R, Lourenco D, Boudjenah R, et al: Mutation analysis of NR5A1 encoding steroidogenic factor 1 in 77 patients with 46,XY disorders of sex development (DSD) including hypospadias. PLoS One 6:e24117 (2011).
2.
Bashamboo A, McElreavey K: Gene mutations associated with anomalies of human gonad formation. Sex Dev 7:126-146 (2013).
3.
Bashamboo A, Ferraz-de-Souza B, Lourenço D, Lin L, Sebire NJ, et al: Human male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1. Am J Hum Genet 8:505-512 (2010).
4.
Bashamboo A, Brauner R, Bignon-Topalovic J, Lortat-Jacob S, Karageorgou V, et al: Mutations in the FOG2/ZFPM2 gene are associated with anomalies of human testis determination. Hum Mol Genet 23:3657-3665 (2014).
5.
Das DK, Rahate SG, Mehta BP, Gawde HM, Tamhankar PM: Mutation analysis of mitogen activated protein kinase 1 gene in Indian cases of 46,XY disorder of sex development. Indian J Hum Genet 19:437-442 (2013).
6.
El-Khairi R, Achermann JC: Steroidogenic factor-1 and human disease. Semin Reprod Med 30:374-381 (2012).
7.
Hughes IA, Houk C, Ahmed SF, Lee PA, Lawson Wilkins Pediatric Endocrine Society/European Society for Paediatric Endocrinology Consensus Group: Consensus statement on management of intersex disorders. J Pediatr Urol 2:148-162 (2006).
8.
Khajavi M, Inoue K, Lupski JR: Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet 14:1074-1081 (2006).
9.
Loke J, Pearlman A, Radi O, Zuffardi O, Giussani U, et al: Mutations in MAP3K1 tilt the balance from SOX9/FGF9 to WNT/β-catenin signaling. Hum Mol Genet 23:1073-1083 (2014).
10.
Lourenço D, Brauner R, Lin L, De Perdigo A, Weryha G, et al: Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med 360:1200-1210 (2009).
11.
Murphy MW, Lee JK, Rojo S, Gearhart MD, Kurahashi K, et al: An ancient protein-DNA interaction underlying metazoan sex determination. Nat Struct Mol Biol 22:442-451 (2015).
12.
Pearlman A, Loke J, Le Caignec C, White S, Chin L, et al: Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. Am J Hum Genet 87:898-905 (2010).
13.
Philibert P, Zenaty D, Lin L, Soskin S, Audran F, et al: Mutational analysis of steroidogenic factor 1 (NR5a1) in 24 boys with bilateral anorchia: a French collaborative study. Hum Reprod 22:3255-3261 (2007).
14.
Suddason T, Gallagher E: A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1. Cell Death Differ 22:540-548 (2015).
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.